Starpharma announces positive final DEP® irinotecan Phase 2 clinical trial results
Posted: 28 May 2024 Starpharma (ASX: SPL, OTCQX: SPHRY), dedicated to helping patients with significant illnesses, such as cancer, achieve improved health outcomes through the application of our unique dendrimer technology, today announces the full results of the Phase…
Phase 2 trial shows significant improvements in Pitt Hopkins syndrome
Posted: 28 May 2024 Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). Statistically significant improvement from baseline was observed by both clinicians and…
Adherium will provide its Hailie Smartinhaler for an AstraZeneca clinical trial
Posted: 27 May 2024 Adherium Limited (“Adherium” or “the Company”; ASX:ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced that AstraZeneca has selected its Hailie® Smartinhaler® platform for a clinical trial. This contract…
Neo-Bionica Announces the Appointment of Stéphane Chatonsky and Dr Colin White to its Board of Directors
Posted: 27 May 2024 Neo-Bionica welcomes two new non-executive directors with extensive international and business experience, to its board. Stéphane and Colin bring expertise that supports and strengthens Neo-Bionica’s domestic and international expansion plans. Stéphane Chatonsky, MBA, GAICD…
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
Posted: 24 May 2024 Telix today announces the successful completion of CUPID1, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate cancer. TLX592 (225Ac-PSMA-RADmAb®) is Telix’s investigational “next generation” targeted alpha therapy (TAT)…
Pancreatic cancer research receives $8m philanthropic funding boost
Posted: 24 May 2024 An exceptional $8 million, 10-year philanthropic investment will spearhead new treatments for pancreatic cancer and create a new dedicated research centre at WEHI. The centre, to be established thanks to an investment by Australian…
CARTHERICS GRANTED EUROPEAN PATENT FOR MULTIPLE DEVELOPMENT CANDIDATES
Posted: 24 May 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its second European Patent from the family…
Stem cell medicine advancements to be showcased at reNEW’s scientific meeting
Posted: 24 May 2024 At a Glance: Emerging treatments for muscle, kidney and heart diseases will be among the stem cell projects showcased at the reNEW Annual Scientific Meeting. MCRI Director Professor Kathryn North AC will open the…
Making an impact at Connecting Women Lunch
Posted: 21 May 2024 On Friday 17 May 2024, BioMelbourne Network hosted 591 amazing industry professionals at Connecting Women Lunch – our premier event of the year – and acknowledged remarkable women in healthtech. This year we changed…
Ubiquitin trailblazer elected Fellow of prestigious Royal Society
Posted: 20 May 2024 WEHI division head and pioneer of ubiquitination Professor David Komander has been elected a Fellow of the esteemed Royal Society, the UK’s national science academy. Prof Komander was recognised for his significant research contributions towards understanding…
Nominations Open For Manufacturing Hall Of Fame
Posted: 20 May 2024 Victoria’s most advanced and innovative manufacturers are being encouraged to nominate for the 2024 Victorian Manufacturing Hall of Fame Awards, supported by the Allan Labor Government. Minister for Jobs and Industry Natalie Hutchins today…
Amplia Therapeutics Successfully Completes $4.27 million Fully Underwritten Entitlement Offer and ACCENT Trial Update
Posted: 15 May 2024 Amplia Therapeutics Limited (ASX: ATX) (Amplia or the Company) is pleased to announce the successful completion of its $4.27 million fully underwritten, non-renounceable entitlement offer which was well supported by existing eligible shareholders and…
